Article Information
History
- October 6, 2022.
Article Versions
- Version 1 (April 5, 2022 - 19:50).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jia-Yuan Zhang1,
- Fiona Hamey1,
- Dominik Trzupek1,
- Marius Mickunas2,
- Mercede Lee1,
- Leila Godfrey1,
- Jennie H.M. Yang2,
- Marcin L Pekalski1,
- Jane Kennet3,4,
- Frank Waldron-Lynch5,
- Mark L. Evans3,4,
- Timothy I. M. Tree2,
- Linda S. Wicker1,†,
- John A. Todd1,†,* and
- Ricardo C. Ferreira1,†,*
- 1JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- 2Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom
- 3Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, United Kingdom
- 4National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke’s Biomedical Campus, Cambridge, United Kingdom
- 5Vertex Pharmaceuticals, Vertex Cell & Gene Therapies, Boston, Massachusetts, United States of America
- ↵*Correspondence: Prof. John A. Todd: Email: john.todd{at}well.ox.ac.uk Dr. Ricardo C. Ferreira: Email: ricardo.ferreira{at}well.ox.ac.uk
Posted October 06, 2022.
Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients
